Uveitis - Epidemiology Forecast–2030

DelveInsight’s ‘Uveitis - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Uveitis, historical and forecasted epidemiology as well as the Uveitis trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Uveitis Disease Understanding
Prevent Blindness Organization defines Uveitis as, a term for inflammation of the eye. It is an inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. Uvea is made up of the iris, ciliary body and choroid.

Uveitis is caused by inflammatory responses inside the eye that can be caused due to tissue damage, germs, or toxins which lead swelling, redness, heat, and destroys tissues as certain white blood cells rush to the affected part.

Uveitis can affect anyone at any age, but it is most commonly seen in working-age adults in their fourth decade. There is a higher prevalence in women. Uveitis is classified anatomically as anterior, intermediate, posterior, or diffuse. Anterior uveitis typically refers to inflammation of the iris and anterior chamber; intermediate uveitis refers to inflammation of the ciliary body and vitreous humor (the jellylike filling in the anterior portion of the eye); and posterior uveitis refers to inflammation of the retina, choroid, or the optic disk (where the optic nerve enters the retina). Diffuse uveitis (panuveitis) implies inflammation of the entire uveal tract.

Uveitis Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Uveitis, Diagnosed Prevalent Population of Uveitis, Gender-specific Diagnosed Prevalent Population of Uveitis, Age-specific Diagnosed Prevalent Population of Uveitis, Type-specific Diagnosed Prevalent Population of Uveitis, Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location, and Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) scenario of uveitis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Uveitis Detailed Epidemiology Segmentation
• As per DelveInsight’s analysis, the total Prevalent Population of Uveitis in the 7MM was found to be 897,466 in 2017. The estimates higher prevalence of Uveitis in the United States with 357,791 cases in 2017.
• Among the European countries, Germany had the maximum prevalent population of Uveitis with 93,260 cases followed by France, which had a prevalent population of 77,331 in 2017.
• In 2017, it was found that there were 28,111 diagnosed cases of infectious uveitis, and 293,901 cases of non-infectious uveitis in the United States.
• In 2017, Acute Anterior Uveitis was accounted for 43.00% of the total cases of Uveitis in the United States. Acute anterior noninfectious uveitis includes Grade 0 and 1, and accounts for 98,670 cases in 2017. While, in the same year, 130,795 cases of chronic anterior noninfectious uveitis out of which Grade 2 has 84,581 cases; Grade 3 has 31,528; and Grade 4 has 14,686 cases respectively.
• Japan accounts second among the 7MM in terms of prevalent cases with 166,478 cases among the 7MM.

Scope of the Report
• The report covers the descriptive overview of Uveitis, explaining its causes, signs and symptoms, and pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Uveitis.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Population of Uveitis, Diagnosed Prevalent Population of Uveitis, Gender-specific Diagnosed Prevalent Population of Uveitis, Age-specific Diagnosed Prevalent Population of Uveitis, Type-specific Diagnosed Prevalent Population of Uveitis, Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location, and Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU).

Report Highlights
• 11-Year Forecast of Uveitis
• 7MM Coverage
• Total Prevalent Population of Uveitis
• Diagnosed Prevalent Population of Uveitis
• Gender-specific Diagnosed Prevalent Population of Uveitis
• Age-specific Diagnosed Prevalent Population of Uveitis
• Type-specific Diagnosed Prevalent Population of Uveitis
• Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
• Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU)

Key Questions Answered
• What is the disease risk, burden and unmet needs of Uveitis?
• What is the historical Uveitis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Uveitis at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Uveitis?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Uveitis during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The Uveitis report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Uveitis epidemiology forecast.
• The Uveitis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Uveitis epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030


1. Key Insight
2. Executive Summary
3. Uveitis Epidemiology Overview at a Glance
3.1. Epidemiology Share (%) Distribution of Uveitis in 2017
3.2. Epidemiology Share (%)Distribution of Uveitis in 2030
4. Disease Background and Overview: Uveitis
4.1. Introduction
4.2. Classification of Uveitis
4.3. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis
4.4. The Standardization of Uveitis Nomenclature (SUN) Working Group
4.5. Symptoms of Uveitis
4.6. Pathophysiology
4.7. Etiology of Uveitis
4.8. Diagnosis of Uveitis
American Academy of Family Physicians
5. Case Reports
5.1. A Case Study of Unusual Etiology of Anterior Uveitis with Ocular Hypertension-Iris Metastasis of Primary Lung Adenocarcinoma
5.2. Blurry Vision and a Black Ink Tattoo
5.3. Psoriatic Juvenile Idiopathic Arthritis Associated with Uveitis: A Case Report
5.4. A Case of Syphilitic Uveitis in Which Vitreous Surgery Was Useful for the Diagnosis and Treatment
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
6.3. Total Prevalent Population of Uveitis in the 7MM
6.4. Total diagnosed Prevalent Population of Uveitis in the 7MM
6.5. Type-specific Diagnosed Prevalent Population of Uveitis in the 7MM
7. United States-Epidemiology of Uveitis
7.1. Assumptions and Rationale
7.2. Total Prevalent Population of Uveitis in the United States
7.3. Diagnosed Prevalent Population of Uveitis in the United States
7.4. Gender-specific Diagnosed Prevalent Population of Uveitis in the United States
7.5. Age-specific Diagnosed Prevalent Population of Uveitis in the United States
7.6. Type-specific Diagnosed Prevalent Population of Uveitis in the United States
7.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
7.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States
8. EU-5 Epidemiology of Uveitis
8.1. Germany
8.1.1. Assumptions and Rationale
8.1.2. Prevalent Population of Uveitis in Germany
8.1.3. Diagnosed Prevalent Population of Uveitis in Germany
8.1.4. Gender-specific Diagnosed Prevalence of Uveitis in Germany
8.1.5. Age-specific Diagnosed Prevalence of Uveitis in Germany
8.1.6. Type-specific Diagnosed Prevalence of Uveitis in Germany
8.1.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
8.1.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany
8.2. France
8.2.1. Assumptions and Rationale
8.2.2. Prevalent Population of Uveitis in France
8.2.3. Diagnosed Prevalent Population of Uveitis in France
8.2.4. Gender-specific Diagnosed Prevalence of Uveitis in France
8.2.5. Age-specific Diagnosed Prevalence of Uveitis in France
8.2.6. Type-specific Diagnosed Prevalence of Uveitis in France
8.2.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
8.2.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France
8.3. Italy
8.3.1. Assumptions and Rationale
8.3.2. Prevalent Population of Uveitis in Italy
8.3.3. Diagnosed Prevalent Population of Uveitis in Italy
8.3.4. Gender-specific Diagnosed Prevalence of Uveitis in Italy
8.3.5. Age-specific Diagnosed Prevalence of Uveitis in Italy
8.3.6. Type-specific Diagnosed Prevalence of Uveitis in Italy
8.3.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
8.3.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy
8.4. Spain
8.4.1. Assumptions and Rationale
8.4.2. Prevalent Population of Uveitis in Spain
8.4.3. Diagnosed Prevalent Population of Uveitis in Spain
8.4.4. Gender-specific Diagnosed Prevalence population of Uveitis in Spain
8.4.5. Age-specific Diagnosed Prevalence of Uveitis in Spain
8.4.6. Type-specific Diagnosed Prevalence of Uveitis in Spain
8.4.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain
8.4.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain
8.5. United Kingdom
8.5.1. Assumptions and Rationale
8.5.2. Prevalent Population of Uveitis in the UK
8.5.3. Diagnosed Prevalent Population of Uveitis in the United Kingdom
8.5.4. Gender-specific Diagnosed Prevalence of Uveitis in the UK
8.5.5. Age-specific Diagnosed Prevalence of Uveitis in the UK
8.5.6. Type-specific Diagnosed Prevalence of Uveitis in the UK
8.5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK
8.5.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK
9. Japan
9.1. Assumptions and Rationale
9.2. Prevalent Population of Uveitis in Japan
9.3. Diagnosed Prevalent Population of Uveitis in Japan
9.4. Gender-specific Prevalence of Uveitis in Japan
9.5. Age-specific Prevalence of Uveitis in Japan
9.6. Type-specific Prevalence of Uveitis in Japan
9.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan
9.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan
10. KOL Views
11. Appendix
12. Report Methodology
12.1. Sources Used
13. DelveInsight Capabilities
14. Disclaimer
15. About DelveInsight
List of Tables
Table 1 Summary of Uveitis, Epidemiology and Key Events (2017–2030)
Table 2 IUSG Clinical Classification of Uveitis
Table 3 The SUN Working Group Anatomic Classification of Uveitis
Table 4 The SUN Working Group Descriptors of Uveitis
Table 5 The SUN Working Group Grading Scheme for Anterior Chamber Cells
Table 6 The SUN Working Group Grading Scheme for Anterior Chamber Cells
Table 7 Key Recommendations For Practice
Table 8 Region-wise Prevalent Population of Uveitis (2017–2030)
Table 9 Diagnosed Prevalent Population of Uveitis (2017–2030)
Table 10 Type-specific Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2030)
Table 11 Total Prevalent Population of Uveitis in the US (2017–2030)
Table 12 Total Diagnosed Prevalent Population of Uveitis in the US (2017–2030)
Table 13 Gender-specific Diagnosed Prevalent Population of Uveitis in the US (2017–2030)
Table 14 Age-specific Diagnosed Prevalent Population of Uveitis in the US (2017–2030)
Table 15 Type-specific Diagnosed Prevalent Population of Uveitis in the US (2017–2030)
Table 16 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the United States (2017–2030)
Table 17 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States (2017–2030)
Table 18 Prevalent Population of Uveitis in Germany (2017–2030)
Table 19 Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Table 20 Gender-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Table 21 Age-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Table 22 Type-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Table 23 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Germany (2017–2030)
Table 24 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany (2017–2030)
Table 25 Prevalent Population of Uveitis in France (2017–2030)
Table 26 Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Table 27 Gender-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Table 28 Age-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Table 29 Type-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Table 30 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in France (2017–2030)
Table 31 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France (2017–2030)
Table 32 Prevalent Population of Uveitis in Italy (2017–2030)
Table 33 Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Table 34 Gender-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Table 35 Age-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Table 36 Type-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Table 37 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Italy (2017–2030)
Table 38 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy (2017–2030)
Table 39 Prevalent Population of Uveitis in Spain (2017–2030)
Table 40 Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Table 41 Gender-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Table 42 Age-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Table 43 Type-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Table 44 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain (2017–2030)
Table 45 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain (2017–2030)
Table 46 Prevalent Population of Uveitis in the UK (2017–2030)
Table 47 Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Table 48 Gender-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Table 49 Age-specific Prevalent Population of Uveitis in the UK (2017–2030)
Table 50 Type-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Table 51 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK (2017–2030)
Table 52 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK (2017–2030)
Table 53 Prevalent Population of Uveitis in Japan (2017–2030)
Table 54 Diagnosed Prevalent Population of Uveitis in Japan (2017–2030)
Table 55 Gender-specific Prevalent Population of Uveitis in Japan (2017–2030)
Table 56 Age-specific Prevalent Population of Uveitis in Japan (2017–2030)
Table 57 Type-specific Prevalent Population of Uveitis in Japan (2017–2030)
Table 58 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan (2017-2030)
Table 59 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan (2017–2030)
List of Figures
Figure 1 Structure of Eye
Figure 2 Types of Uveitis and Affected area
Figure 3 Classification of Uveitis
Figure 4 Types of Uveitis are based on the different parts of eye. Below are the four types
Figure 5 Symptoms of Uveitis
Figure 6 Pathogenetic mechanism of Uveitis
Figure 7 Mechanism of antigen processing and presentation.
Figure 8 Autoimmune conditions that cause uveitis
Figure 9 Causes of Uveitis
Figure 10 Diagnosis algorithm for Uveitis
Figure 11 Prevalent Population of Uveitis in the 7MM (2017–2030)
Figure 12 Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2030)
Figure 13 Type-specific Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2030)
Figure 14 Total Prevalent Population of Uveitis in the United States (2017–2030)
Figure 15 Diagnosed Prevalent Population of Uveitis in the United States (2017–2030)
Figure 16 Gender-specific Diagnosed Prevalent Population of Uveitis in the United States (2017–2030)
Figure 17 Age-specific Diagnosed Prevalent Population of Uveitis in the United States (2017–2030)
Figure 18 Type-specific Diagnosed Prevalent Population of Uveitis in the US (2017–2030)
Figure 19 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the United States (2017–2030)
Figure 20 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States (2017–2030)
Figure 21 Prevalent Population of Uveitis in Germany (2017–2030)
Figure 22 Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Figure 23 Gender-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Figure 24 Age-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Figure 25 Type-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Figure 26 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Germany (2017–2030)
Figure 27 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany 2017–2030)
Figure 28 Prevalent Population of Uveitis in France (2017–2030)
Figure 29 Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Figure 30 Gender-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Figure 31 Age-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Figure 32 Type-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Figure 33 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in France (2017–2030)
Figure 34 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France (2017–2030)
Figure 35 Prevalent Population of Uveitis in Italy (2017–2030)
Figure 36 Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Figure 37 Gender-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Figure 38 Age-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Figure 39 Type-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Figure 40 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Italy (2017–2030)
Figure 41 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy (2017–2030)
Figure 42 Prevalent Population of Uveitis & Non-Infectious Uveitis (NIU) in Spain (2017–2030)
Figure 43 Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Figure 44 Gender-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Figure 45 Age-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Figure 46 Type-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Figure 47 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain (2017–2030)
Figure 48 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain (2017–2030)
Figure 49 Prevalent Population of Uveitis in the UK (2017–2030)
Figure 50 Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Figure 51 Gender-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Figure 52 Age-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Figure 53 Type-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Figure 54 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK (2017–2030)
Figure 55 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK (2017–2030)
Figure 56 Prevalent Population of Uveitis in Japan (2017–2030)
Figure 57 Diagnosed Prevalent Population of Uveitis in Japan (2017–2030)
Figure 58 Gender-specific Prevalent Population of Uveitis in Japan (2017–2030)
Figure 59 Age-specific Prevalent Population of Uveitis in Japan (2017–2030)
Figure 60 Type Specific Prevalent Population of Uveitis in Japan (2017–2030)
Figure 61 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan (2017-2030)
Figure 62 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan (2017–2030)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook